Corning Awarded Additional Patent for Label-free Drug Development Technology
21 Maggio 2008 - 1:45PM
Business Wire
Corning Incorporated (NYSE:GLW) today announced that the United
States Patent and Trademark Office issued the company an additional
patent related to the Corning� Epic� System that deals with the
study of unpurified biological samples with label-free biosensor
technology. This advanced discovery will enable researchers to
study the interactions between drug targets and more biologically
relevant samples such as cell supernatants and cell lysates. It
will also help to improve overall data quality and reduce the time
and expense associated with identifying and labeling drug targets.
The study of molecular interactions in high-throughput screening
has become an essential part of the drug discovery process. Many
conventional screening methods require highly purified molecules as
well as complex labeling methods, both of which can compromise the
biological relevance of the interactions being studied.
Applications such as hybridoma screening and cell lysates require
the ability to detect biomolecular interactions in complex samples.
�The ability of the Corning Epic System to screen complex samples
such as cell lysates and supernatants in drug discovery represents
a significant step forward in rapidly identifying novel and
biologically relevant interactions,� said Mannix Aklian, commercial
development manager and the Corning inventor responsible for this
new patent. This latest patent, U.S. Patent No. 7,349,080 entitled
�Label-independent Detection of Unpurified Analytes,� adds to
Corning�s extensive patent portfolio related to the Epic System and
label-free, optical biosensor technology. Previously, Corning
acquired exclusive rights to U.S. Patent No. 5,738,825, a
fundamental patent related to optical-based biosensors in a
microplate format. �We are committed to enabling our customers to
realize the great potential of label-free technology in drug
discovery and beyond,� said Ron Verkleeren, Epic business director,
Corning Incorporated. Corning�s Epic system is the world�s first
high-throughput, label-free screening system. It uses patented
optical biosensor technology to enable the study of a broad range
of biochemical and cell-based targets. Corning launched the system
in 2006 and deployed it at customer sites in North America, Europe
and Asia. For additional information on the Epic System or any
other Corning Life Sciences products, please contact a customer
service representative at 1-800-492-1110, toll free in the United
States, (+1) 978-442-2200 internationally, or visit
www.corning.com/epic. About Corning Corning Incorporated
(www.corning.com) is the world leader in specialty glass and
ceramics. Drawing on more than 150 years of materials science and
process engineering knowledge, Corning creates and makes keystone
components that enable high-technology systems for consumer
electronics, mobile emissions control, telecommunications and life
sciences. Our products include glass substrates for LCD
televisions, computer monitors and laptops; ceramic substrates and
filters for mobile emission control systems; optical fiber, cable,
hardware & equipment for telecommunications networks; optical
biosensors for drug discovery; and other advanced optics and
specialty glass solutions for a number of industries including
semiconductor, aerospace, defense, astronomy and metrology.
Grafico Azioni Corning (NYSE:GLW)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Corning (NYSE:GLW)
Storico
Da Lug 2023 a Lug 2024